Neuronal nicotinic acetylcholine receptor alpha-4 beta-2 subtype (α4β2 nAChR) (α4β2 nAChR)

The alpha-4 beta-2 (α4β2) nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel and the most prevalent high-affinity nicotinic receptor subtype in the mammalian brain [IUPHAR/BPS Guide to Pharmacology]. It is primarily located on presynaptic terminals and postsynaptic neurons in regions such as the thalamus, cortex, and the mesolimbic dopamine system, where it modulates the release of various neurotransmitters, including dopamine, GABA, and glutamate [PubMed: 21840305]. This receptor plays a critical role in cognitive processes, reward pathways, and the mediation of nicotine's reinforcing effects, making it a primary target for smoking cessation therapies [StatPearls: Nicotinic Receptors]. Dysregulation or mutations in the subunits of this receptor are linked to conditions like Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE) and cognitive decline in neurodegenerative diseases [UniProt: P43681]. Pharmacological intervention often involves partial agonists that stabilize the receptor in a desensitized state or provide controlled activation to alleviate withdrawal symptoms in addiction [Nature Reviews Drug Discovery]. Additionally, positive allosteric modulators and antagonists are being investigated for their potential in treating mood disorders and chronic pain [PubMed: 25113125].

Other names

alpha4beta2 nicotinic receptornAChR alpha4beta2CHRNA4/CHRNB2 complexNeuronal acetylcholine receptor alpha-4 beta-2α4β2* nAChRCHRNA4CHRNB2

Drugs targeting the α4β2 nAChR typically act as agonists or partial agonists to stimulate or modulate cholinergic signaling, or as antagonists to block the effects of nicotine [IUPHAR/BPS Guide to Pharmacology]. Partial agonists like varenicline provide enough stimulation to reduce withdrawal symptoms while blocking the rewarding effects of nicotine by competing for the same binding site [FDA: Chantix Label]. Positive allosteric modulators (PAMs) like galantamine enhance the receptor's response to endogenous acetylcholine without directly activating the channel [PubMed: 17499074].